Where it comes from

Made in
Chromaffin cells of the adrenal medulla and sympathetic nerve endings, released with catecholamines
Sent out by
With adrenaline and noradrenaline, as a brake on their own release
Acts on
  • Chromaffin cells
  • Sympathetic nerve terminals
  • Heart
  • Vessels (histamine release from mast cells)

What it does

  • Shuts off catecholamine release, a negative feedback on the cells that made it 1
  • Lowers blood pressure and slows the heart
  • Kills bacteria and fungi in the laboratory

In medicine

  • Catestatin is already low in the still-healthy children of people with hypertension, and the Gly364Ser variant changes autonomic function and lowers diastolic pressure by about 5 to 6 mmHg 2
  • No approved test and no medicine. Chromogranin A, the protein it comes from, is measured as a neuroendocrine tumour marker, and that result says nothing about catestatin
  • Measuring it is the hard part. It is one cut piece of a storage protein that is chopped into many fragments, and the antibodies in use differ in which fragments they see, so published concentrations differ by more than the diseases do 3

Beyond the body’s own use

  • A fragment of a storage protein is not a hormone with a gene of its own. Chromogranin A packages catecholamines inside the granule, and catestatin is one of the pieces left when that package is processed, so how much exists is a question about processing rather than about CHGA expression 1
  • It is studied as a marker in heart failure, where plasma concentrations predicted death or unplanned admission over two years in a 52-patient cohort; nothing of the kind is in clinical use 3
  • It lowers blood pressure in hypertensive rats and kills microbes in a dish. No human trial has been registered, and the measurement problem above is why one would be hard to design 2

Sources

  1. Mahata et al., Novel autocrine feedback control of catecholamine release, Journal of Clinical Investigation 1997
  2. Rao et al., Catestatin variant Gly364Ser and human autonomic activity, Circulation 2007
  3. Wołowiec et al., Catestatin as a prognostic marker in heart failure with reduced ejection fraction, Disease Markers 2020

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.